Overview
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received from Gilead Sciences.
Last reviewed: 23 August 2017
Next review: We will review this decision if the company decides to make a submission